علاج سرطان الخلايا القاعدية النقيلي للجلد

Advanced BCC includes locally advanced BCC (laBCC) and metastatic BCC (mBCC).

Hedgehog inhibitors should be offered to patients with locally advanced or metastatic BCC.

Vismodegib and sonidegib are specific inhibitors of an oncogenic protein named Smoothened and are both approved by FDA and EMA for the treatment of patients with laBCC who are not candidates for surgery or radiotherapy; vismodegib is also approved for mBCC whereas sonidegib is approved for mBCC only in Switzerland and Australia.